• Founded: 2019
  • Location: Toronto, ON
  • Employee range: 11 - 50
  • Clinical stage: Clin1
  • Therapy area: Major depressive disorder
  • Drug types: PSY, NEU, ABU
  • Lead product: CYB003
  • Product link:
  • Funding: 100-500M

job board

Short description:


Drug notes:

Also Clin0 alcohol use disorder; CYB004 Clin1 anxiety; CYB005 RD neuroinflammation

Long description:

Cybin is working to progress psychedelics to therapeutics to revolutionize mental healthcare. Psychedelics are molecules that affect perception and can produce intense subjective experiences. Using their engineering proprietary drug discovery platforms, drug delivery systems and novel formulation approaches, Cybin is developing a range of novel therapies based on psychedelics to address the unmet needs of many mental health issues. Cybin is testing their therapies with cutting-edge neuroimaging technology to generate quantitative data to understand the psychedelic mechanisms of action. Currently, Cybin has 3 active drug programs targeting major depressive disorder, alcohol use disorder, anxiety disorders and neuroinflammation and is progressing lead programs toward FDA and IND filings.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy